Epalex: Funding, Investors & Team (Sep 2026)
EpaleX is developing a novel inhaled treatment for epilepsy and migraine. The treatment for the first time provides a way for patients with epilepsy to gain control over their seizures. When a seizure warning sign (aura) occurs, the patient will be able to prevent the development of a full-blown seizure through the use of a pocket nebulizer to deliver a powerful antiseizure medication that rapidly enters the brain and stops the seizure. The effect of the drug dissipates within minutes, allowing the patient to resume normal daily activity. The inhaler is also used to stop migraine attacks that are refractory to currently available migraine treatments.
Epalex has raised $9.5M across 3 funding rounds on record, the most recent an undisclosed round of $1.2M announced in Nov 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Epalex Company Profile and Key Stats
Latest funding round on record: Nov 2025.
Epalex Funding Rounds
Epalex raised $4.3M in an undisclosed round announced in Oct 2022.
2.2 years later, an undisclosed round of $4.0M was announced in Dec 2024.
11 months later, an undisclosed round of $1.2M was announced in Nov 2025.
Epalex Founders and Leadership Team
Contact details for the Epalex team: 2 of 2 have an email address on file.
Start 14-day free trial →Epalex Funding Compared to Other Biotechnology Startups
Epalex's latest round of $1.2M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Epalex in Biotechnology and Palo Alto
Companies Similar to Epalex
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Epalex Funding FAQs
What does Epalex do?
EpaleX is developing a novel inhaled treatment for epilepsy and migraine. The treatment for the first time provides a way for patients with epilepsy to gain control over their seizures. When a seizure warning sign (aura) occurs, the patient will be able to prevent the development of a full-blown seizure through the use of a pocket nebulizer to deliver a powerful antiseizure medication that rapidly enters the brain and stops the seizure. The effect of the drug dissipates within minutes, allowing the patient to resume normal daily activity. The inhaler is also used to stop migraine attacks that are refractory to currently available migraine treatments.
How much funding has Epalex raised?
Epalex has raised $9.5M across 3 rounds on record. The most recent is an undisclosed round of $1.2M announced in Nov 2025.
When did Epalex last raise funding?
Epalex's most recent funding round on record is an undisclosed round of $1.2M, announced in Nov 2025.
Who founded Epalex?
FundedIQ lists Randall Murphy (Founder) at Epalex.
Who is the CEO of Epalex?
Brendan Magrab is listed as CEO at Epalex.
Where is Epalex headquartered?
Epalex is based in Palo Alto, California, United States.
How many employees does Epalex have?
Epalex is in the 1-10 employee band.
How does Epalex's funding compare to other Biotechnology startups?
Epalex's latest round of $1.2M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Epalex Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Epalex is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.